Phorbol myristate acetate stimulates degradation of a structural analogue of platelet-activating factor to a neutral lipid in human leukemic K562 cells

Relevance to the release of lipids

Toshihiko Tsutsumi, Akira Tokumura, Masaya Yamaguchi, Shikifumi Kitazawa, Yusuke Tanigawara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In our attempt to investigate the mechanism of the release of platelet-activating factor (PAF) from cells, the erythroleukemic cell line K562 was preloaded with a radiolabeled PAF analogue having an ethylcarbamyl residue, 1-O-octadecyl-2-O-ethylcarbamyl-sn-glycero-3-phosphocholine (ethylcarbamyl-PAF), that is resistant to the hydrolytic action of PAF acetylhydrolase. Its extracellular release was monitored using an albumin back-extraction method, and its metabolic degradation was analyzed by TLC. Phorbol myristate acetate (PMA) was found to stimulate the release of two radioactive lipids, ethylcarbamyl-PAF itself and its metabolite, 1-O-octadecyl-2-ethylcarbamyl-sn-glycerol, whereas only ethylcarbamyl-PAF was released from the resting cells. The increased release of radioactive lipids in PMA-stimulated cells was suggested to be due to stimulated degradation of intracellular ethylcarbamyl-PAF into the cell-permeable metabolite. Thus K562 cells have much less capacity to release intact PAF-like lipid in comparison with its high ability to uptake exogenously added PAF analogues previously described by us and others.

Original languageEnglish
Pages (from-to)24-28
Number of pages5
JournalBiological and Pharmaceutical Bulletin
Volume27
Issue number1
DOIs
Publication statusPublished - 2004 Jan

Fingerprint

K562 Cells
Platelet Activating Factor
Tetradecanoylphorbol Acetate
Lipids
Phosphorylcholine
Glycerol
Albumins
Cell Line

Keywords

  • K562 cell
  • Octadecyl-ethylcarbamyl-glycerol
  • PAF analogue
  • Phorbol myristate acetate
  • Platelet-activating factor (PAF)

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Phorbol myristate acetate stimulates degradation of a structural analogue of platelet-activating factor to a neutral lipid in human leukemic K562 cells : Relevance to the release of lipids. / Tsutsumi, Toshihiko; Tokumura, Akira; Yamaguchi, Masaya; Kitazawa, Shikifumi; Tanigawara, Yusuke.

In: Biological and Pharmaceutical Bulletin, Vol. 27, No. 1, 01.2004, p. 24-28.

Research output: Contribution to journalArticle

@article{23ee67e075824dfeb123dfb3d5a6e101,
title = "Phorbol myristate acetate stimulates degradation of a structural analogue of platelet-activating factor to a neutral lipid in human leukemic K562 cells: Relevance to the release of lipids",
abstract = "In our attempt to investigate the mechanism of the release of platelet-activating factor (PAF) from cells, the erythroleukemic cell line K562 was preloaded with a radiolabeled PAF analogue having an ethylcarbamyl residue, 1-O-octadecyl-2-O-ethylcarbamyl-sn-glycero-3-phosphocholine (ethylcarbamyl-PAF), that is resistant to the hydrolytic action of PAF acetylhydrolase. Its extracellular release was monitored using an albumin back-extraction method, and its metabolic degradation was analyzed by TLC. Phorbol myristate acetate (PMA) was found to stimulate the release of two radioactive lipids, ethylcarbamyl-PAF itself and its metabolite, 1-O-octadecyl-2-ethylcarbamyl-sn-glycerol, whereas only ethylcarbamyl-PAF was released from the resting cells. The increased release of radioactive lipids in PMA-stimulated cells was suggested to be due to stimulated degradation of intracellular ethylcarbamyl-PAF into the cell-permeable metabolite. Thus K562 cells have much less capacity to release intact PAF-like lipid in comparison with its high ability to uptake exogenously added PAF analogues previously described by us and others.",
keywords = "K562 cell, Octadecyl-ethylcarbamyl-glycerol, PAF analogue, Phorbol myristate acetate, Platelet-activating factor (PAF)",
author = "Toshihiko Tsutsumi and Akira Tokumura and Masaya Yamaguchi and Shikifumi Kitazawa and Yusuke Tanigawara",
year = "2004",
month = "1",
doi = "10.1248/bpb.27.24",
language = "English",
volume = "27",
pages = "24--28",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "1",

}

TY - JOUR

T1 - Phorbol myristate acetate stimulates degradation of a structural analogue of platelet-activating factor to a neutral lipid in human leukemic K562 cells

T2 - Relevance to the release of lipids

AU - Tsutsumi, Toshihiko

AU - Tokumura, Akira

AU - Yamaguchi, Masaya

AU - Kitazawa, Shikifumi

AU - Tanigawara, Yusuke

PY - 2004/1

Y1 - 2004/1

N2 - In our attempt to investigate the mechanism of the release of platelet-activating factor (PAF) from cells, the erythroleukemic cell line K562 was preloaded with a radiolabeled PAF analogue having an ethylcarbamyl residue, 1-O-octadecyl-2-O-ethylcarbamyl-sn-glycero-3-phosphocholine (ethylcarbamyl-PAF), that is resistant to the hydrolytic action of PAF acetylhydrolase. Its extracellular release was monitored using an albumin back-extraction method, and its metabolic degradation was analyzed by TLC. Phorbol myristate acetate (PMA) was found to stimulate the release of two radioactive lipids, ethylcarbamyl-PAF itself and its metabolite, 1-O-octadecyl-2-ethylcarbamyl-sn-glycerol, whereas only ethylcarbamyl-PAF was released from the resting cells. The increased release of radioactive lipids in PMA-stimulated cells was suggested to be due to stimulated degradation of intracellular ethylcarbamyl-PAF into the cell-permeable metabolite. Thus K562 cells have much less capacity to release intact PAF-like lipid in comparison with its high ability to uptake exogenously added PAF analogues previously described by us and others.

AB - In our attempt to investigate the mechanism of the release of platelet-activating factor (PAF) from cells, the erythroleukemic cell line K562 was preloaded with a radiolabeled PAF analogue having an ethylcarbamyl residue, 1-O-octadecyl-2-O-ethylcarbamyl-sn-glycero-3-phosphocholine (ethylcarbamyl-PAF), that is resistant to the hydrolytic action of PAF acetylhydrolase. Its extracellular release was monitored using an albumin back-extraction method, and its metabolic degradation was analyzed by TLC. Phorbol myristate acetate (PMA) was found to stimulate the release of two radioactive lipids, ethylcarbamyl-PAF itself and its metabolite, 1-O-octadecyl-2-ethylcarbamyl-sn-glycerol, whereas only ethylcarbamyl-PAF was released from the resting cells. The increased release of radioactive lipids in PMA-stimulated cells was suggested to be due to stimulated degradation of intracellular ethylcarbamyl-PAF into the cell-permeable metabolite. Thus K562 cells have much less capacity to release intact PAF-like lipid in comparison with its high ability to uptake exogenously added PAF analogues previously described by us and others.

KW - K562 cell

KW - Octadecyl-ethylcarbamyl-glycerol

KW - PAF analogue

KW - Phorbol myristate acetate

KW - Platelet-activating factor (PAF)

UR - http://www.scopus.com/inward/record.url?scp=3442882559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3442882559&partnerID=8YFLogxK

U2 - 10.1248/bpb.27.24

DO - 10.1248/bpb.27.24

M3 - Article

VL - 27

SP - 24

EP - 28

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 1

ER -